This was the stock's fourth consecutive day of gains.

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

This was the stock's second consecutive day of losses.

Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Plus more pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter.

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform ...

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing ...

Kirkland & Ellis lawyers withdrew from representing Novartis AG in a lawsuit against Regeneron Inc. a week after the firm was challenged over a potential conflict of interest.

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on ...